In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia

Executive Summary

Britain’s Cancer Research Technology says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.

Advertisement

Related Content

AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine
Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate
AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
Deals Of The Week Watches An Unlikely HCIT Partnership: GSK & Community Care of North Carolina
Can Merck Serono Bounce Back?
Astex Aims To Make Cancer Drug Resistance Futile
Cancer Research Technology Ltd.: Biopharma's Gateway to Cancer-Focused Academic Research

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel